The efficacy of mometasone furoate for children with asthma: a meta-analysis of randomized controlled trials

Yanling Song; Kaiyu Pan; Yuyan Chen; Xiaoming Wang; Jun Tian

doi:10.5114/ada.2020.93273

eISSN: 2299-0046
ISSN: 1642-395X

Advances in Dermatology and Allergology/Postępy Dermatologii i Alergologii

Current issue Archive Manuscripts accepted About the journal Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures

Editorial System

Submit your Manuscript

Editorial Policies

Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

5/2021
vol. 38

Send email

Copy url:

abstract:

Review paper

The efficacy of mometasone furoate for children with asthma: a meta-analysis of randomized controlled trials

Yanling Song

¹

,

Kaiyu Pan

²

,

Yuyan Chen

¹

,

Xiaoming Wang

¹

,

Jun Tian

²

Department of Paediatrics, The First Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, Zhejiang Province, China
Department of Paediatrics, The First People’s Hospital of Xiaoshan, Hangzhou, Zhejiang Province, China

Adv Dermatol Allergol 2021; XXXVIII (5): 740-745

DOI: https://doi.org/10.5114/ada.2020.93273

Online publish date: 2020/02/25

View full text Get citation

Introduction
The influence of mometasone furoate for paediatric asthma remains controversial.

Aim
We conducted a systematic review and meta-analysis to explore the efficacy and safety of mometasone furoate for paediatric asthma.

Material and methods
We have searched PubMed, Embase, Web of science, EBSCO, and Cochrane library databases through October 2019 for randomized controlled trials assessing the effect of mometasone furoate versus placebo for paediatric asthma. This meta-analysis was performed using the random-effects model.

Results
Four RCTs were included in the meta-analysis. Overall, as compared to placebo for paediatric asthma, mometasone furoate is associated with substantially increased predicted forced expiratory volume in 1 s (FEV1) (mean difference (MD) = 7.53; 95% CI: 7.02–8.04; p < 0.00001), FEV1 (MD = 0.11; 95% CI: 0.10–0.12; p < 0.00001), and morning peak expiratory flow (AM PEF) (MD = 17.70; 95% CI: 9.91–25.49; p < 0.00001), but demonstrates no obvious effect on pharyngitis (RR = 0.96; 95% CI: 0.59–1.58; p = 0.89), upper respiratory tract infections (RR = 0.73; 95% CI: 0.50–1.05; p = 0.09), or adverse events (RR = 1.05; 95% CI: 0.84–1.31; p = 0.69).

Conclusions
Mometasone furoate may be effective and safe for paediatric asthma.

keywords:

The efficacy of mometasone furoate for children with asthma: a meta-analysis of randomized controlled trials

Yanling Song 1 , Kaiyu Pan 2 , Yuyan Chen 1 , Xiaoming Wang 1 , Jun Tian 2

mometasone furoate, paediatric asthma, forced expiratory volume in 1 s, randomized controlled trials

Yanling Song

¹

,

Kaiyu Pan

²

,

Yuyan Chen

¹

,

Xiaoming Wang

¹

,

Jun Tian

²